Hydromorphone

CHEMBL398707 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

2-3 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

285.3 g/mol

LogP

1.8

Phase

4

A potent opioid analgesic used to treat moderate to severe pain, including cancer pain and postoperative pain, by binding to opioid receptors in the central nervous system to reduce pain perception. It is several times more potent than morphine and is available in oral, intravenous, and subcutaneous formulations. Careful dose titration and monitoring for respiratory depression are essential during use.

น้ำหนักโมเลกุล

285.3380 g/mol

LogP

1.80

TPSA

49.80 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Migraine Obesity Hypertension Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

หมวดหมู่ยา

N — N - Nervous System

กลไกการออกฤทธิ์

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

Pharmacokinetics (PK)

Half-Life 2-3 hours

Pharmacodynamics (PD)

กลไก

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5

InChI

InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1

Molecular Formula

C17H19NO3

HBD / HBA

1 / 4

พันธะที่หมุนได้

0

อะตอมหนัก

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A potent opioid analgesic used to treat moderate to severe pain, including cancer pain and postoperative pain, by binding to opioid receptors in the central nervous system to reduce pain perception. It is several times more potent than morphine and is available in oral, intravenous, and subcutaneous formulations. Careful dose titration and monitoring for respiratory depression are essential during use.

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

Key pharmacokinetic parameters for Hydromorphone: Half-life: 2-3 hours.

Yes, Hydromorphone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

Same Drug Class

Acetaminophen Small molecule Aspirin Small molecule Sertraline Small molecule Escitalopram Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL398707. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5284570. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Hydromorphone บน PillFYI

โครงสร้าง

ข้อมูลด่วน

Class: N - Nervous System
สูตร: C17H19NO3
คำพ้องความหมาย: 3

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Hydromorphone

ด้านการรักษา

หมวดหมู่ยา

กลไกการออกฤทธิ์

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

คำถามที่พบบ่อย

Related Drugs

Same Drug Class

References & Data Sources

Embed This Widget